These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 33010161)

  • 1. Recommended Definitions of Aggressive Prostate Cancer for Etiologic Epidemiologic Research.
    Hurwitz LM; Agalliu I; Albanes D; Barry KH; Berndt SI; Cai Q; Chen C; Cheng I; Genkinger JM; Giles GG; Huang J; Joshu CE; Key TJ; Knutsen S; Koutros S; Langseth H; Li SX; MacInnis RJ; Markt SC; Penney KL; Perez-Cornago A; Rohan TE; Smith-Warner SA; Stampfer MJ; Stopsack KH; Tangen CM; Travis RC; Weinstein SJ; Lang PhD W; Jacobs EJ; Mucci LA; Platz EA; Cook MB;
    J Natl Cancer Inst; 2021 Jun; 113(6):727-734. PubMed ID: 33010161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Applying recommended definition of aggressive prostate cancer: a validation study using high-quality data from the Cancer Registry of Norway.
    Robsahm TE; Tsuruda KM; Hektoen HH; Storås AH; Cook MB; Hurwitz LM; Langseth H
    Acta Oncol; 2023 Jan; 62(1):8-14. PubMed ID: 36762472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Defining aggressive prostate cancer: a geospatial perspective.
    Wiese D; DuBois TD; Sorice KA; Fang CY; Ragin C; Daly MB; Reese AC; Henry KA; Lynch SM
    BMC Cancer; 2023 Aug; 23(1):754. PubMed ID: 37580675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence and Predictors of Upgrading and Up Staging among 10,000 Contemporary Patients with Low Risk Prostate Cancer.
    Dinh KT; Mahal BA; Ziehr DR; Muralidhar V; Chen YW; Viswanathan VB; Nezolosky MD; Beard CJ; Choueiri TK; Martin NE; Orio PF; Sweeney CJ; Trinh QD; Nguyen PL
    J Urol; 2015 Aug; 194(2):343-9. PubMed ID: 25681290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of an Aggressive Prostate Biopsy Strategy in Men Younger than 50 Years.
    Goldberg H; Klaassen Z; Chandrasekar T; Wallis CJD; Toi A; Sayyid R; Bhindi B; Nesbitt M; Evans A; van der Kwast T; Sweet J; Perlis N; Hamilton RJ; Kulkarni GS; Finelli A; Zlotta A; Fleshner N
    J Urol; 2018 Nov; 200(5):1056-1061. PubMed ID: 29758220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic accuracy of [-2]proPSA versus Gleason score and Prostate Health Index versus Gleason score for the determination of aggressive prostate cancer: a systematic review.
    Anyango R; Ojwando J; Mwita C; Mugalo E
    JBI Evid Synth; 2021 Jun; 19(6):1263-1291. PubMed ID: 33741840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study.
    Brown LC; Ahmed HU; Faria R; El-Shater Bosaily A; Gabe R; Kaplan RS; Parmar M; Collaco-Moraes Y; Ward K; Hindley RG; Freeman A; Kirkham A; Oldroyd R; Parker C; Bott S; Burns-Cox N; Dudderidge T; Ghei M; Henderson A; Persad R; Rosario DJ; Shergill I; Winkler M; Soares M; Spackman E; Sculpher M; Emberton M
    Health Technol Assess; 2018 Jul; 22(39):1-176. PubMed ID: 30040065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of prostate-specific antigen density on positive and negative predictive values of multiparametric magnetic resonance imaging to detect Gleason score 7-10 prostate cancer in a repeat biopsy setting.
    Hansen NL; Barrett T; Koo B; Doble A; Gnanapragasam V; Warren A; Kastner C; Bratt O
    BJU Int; 2017 May; 119(5):724-730. PubMed ID: 27488931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.
    Klein EA; Cooperberg MR; Magi-Galluzzi C; Simko JP; Falzarano SM; Maddala T; Chan JM; Li J; Cowan JE; Tsiatis AC; Cherbavaz DB; Pelham RJ; Tenggara-Hunter I; Baehner FL; Knezevic D; Febbo PG; Shak S; Kattan MW; Lee M; Carroll PR
    Eur Urol; 2014 Sep; 66(3):550-60. PubMed ID: 24836057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men.
    Preston MA; Gerke T; Carlsson SV; Signorello L; Sjoberg DD; Markt SC; Kibel AS; Trinh QD; Steinwandel M; Blot W; Vickers AJ; Lilja H; Mucci LA; Wilson KM
    Eur Urol; 2019 Mar; 75(3):399-407. PubMed ID: 30237027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database.
    Mithal P; Howard LE; Aronson WJ; Kane CJ; Cooperberg MR; Terris MK; Amling CL; Freedland SJ
    Int J Urol; 2015 Apr; 22(4):362-6. PubMed ID: 25728968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Critical assessment of prebiopsy parameters for predicting prostate cancer metastasis and mortality.
    van Leeuwen PJ; van den Bergh RC; Wolters T; Zhu X; Bul M; Schröder FH; Bangma CH; Roobol MJ
    Can J Urol; 2011 Dec; 18(6):6018-24. PubMed ID: 22166329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and Validation of a Lookup Table for the Prediction of Metastatic Prostate Cancer According to Prostatic-specific Antigen Value, Clinical Tumor Stage, and Gleason Grade Groups.
    Preisser F; Bandini M; Nazzani S; Mazzone E; Marchioni M; Tian Z; Chun FKH; Saad F; Briganti A; Haese A; Montorsi F; Huland H; Graefen M; Tilki D; Karakiewicz PI
    Eur Urol Oncol; 2020 Oct; 3(5):631-639. PubMed ID: 31411975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathologic features and determinants of Gleason score of prostate cancer in Ghanaian men.
    Yarney J; Vanderpuye V; Mensah J
    Urol Oncol; 2013 Apr; 31(3):325-30. PubMed ID: 21441045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Towards an optimal interval for prostate cancer screening.
    van Leeuwen PJ; Roobol MJ; Kranse R; Zappa M; Carlsson S; Bul M; Zhu X; Bangma CH; Schröder FH; Hugosson J
    Eur Urol; 2012 Jan; 61(1):171-6. PubMed ID: 21840117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The U Shape of Prostate-specific Antigen and Prostate Cancer-specific Mortality in High-grade Metastatic Prostate Adenocarcinoma.
    Wang J; Abudurexiti M; Shao N; Wei Y; Zhu Y; Ye DW
    Eur Urol Focus; 2020 Jan; 6(1):53-62. PubMed ID: 30217630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic Impacts of Clinical Laboratory Based p2PSA Indexes on any Grade, Gleason Grade Group 2 or Greater, or 3 or Greater Prostate Cancer and Prostate Specific Antigen below 10 ng/ml.
    Ito K; Yokomizo A; Tokunaga S; Arai G; Sugimoto M; Akakura K; Hasumi H; Sakai H; Ouraji A; Oki R; Kashiwagi E; Kobori Y; Hirama H; Kitoh H; Uemura H; Hakariya T; Suzuki K;
    J Urol; 2020 Jan; 203(1):83-91. PubMed ID: 31430244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can multiparametric magnetic resonance imaging predict upgrading of transrectal ultrasound biopsy results at more definitive histology?
    Abd-Alazeez M; Ahmed HU; Arya M; Allen C; Dikaios N; Freeman A; Emberton M; Kirkham A
    Urol Oncol; 2014 Aug; 32(6):741-7. PubMed ID: 24981993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Magnetic Resonance and Ultrasound Image Fusion Supported Transperineal Prostate Biopsy Using the Ginsburg Protocol: Technique, Learning Points, and Biopsy Results.
    Hansen N; Patruno G; Wadhwa K; Gaziev G; Miano R; Barrett T; Gnanapragasam V; Doble A; Warren A; Bratt O; Kastner C
    Eur Urol; 2016 Aug; 70(2):332-40. PubMed ID: 26995327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of Pathologic Upgrading or Locally Advanced Disease in Early Prostate Cancer Patients Based on Biopsy Gleason Score and PSA: A Population-Based Study of Modern Patients.
    Caster JM; Falchook AD; Hendrix LH; Chen RC
    Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):244-51. PubMed ID: 25841621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.